SLC5A2 and heart failure: Thus, recommendations for SGLT2 inhibitors in heart failure with mildly reduced and preserved ejection fraction remain absent, partly due to uncertainty around the consistency of clinical benefits across the HF classes and therapeutic effects, particularly cardiovascular death.